readthroughSign in
Nov 12, 2026Quarterly update

Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer IND

Eikon Therapeutics disclosed updated lung cancer data, a registrational trial start, and an IND filing for a new prostate cancer drug, alongside $461.7 million in cash.

Eikon Therapeutics reported third quarter 2026 results on November 12, 2026, highlighting several oncology pipeline updates alongside its financials.

At the 2026 European Society for Medical Oncology Congress on October 26, 2026, Eikon presented updated data from TeLuRide-005, an ongoing open-label Phase 2 trial evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy in non-small cell lung cancer, showing an objective response rate of 63.1% and disease control rate of 89.2% across 65 efficacy-evaluable patients at a median follow-up of 17.2 months.1 The squamous cohort showed a 72.4% ORR and 100% DCR with median duration of response of 12.9 months, while the non-squamous cohort showed a 55.6% ORR and 80.6% DCR with median DOR of 11.2 months.1

On July 27, 2026, Eikon announced dosing of the first patient in TeLuRide-008, a Phase 2/3 trial titled evaluating EIK1001 with pembrolizumab and chemotherapy as first-line therapy for treatment-naive stage 4 NSCLC patients.1 The trial is actively enrolling, with an interim analysis for dose selection expected in the second half of 2027.1

Eikon also reported PARP1 inhibitor data for EIK1003 and EIK1004, and early results from its WRN helicase inhibitor EIK1005, including a partial response in the first patient dosed in the pembrolizumab combination arm.

On October 14, 2026, Eikon submitted an IND application to the FDA to evaluate EIK1006, a next-generation androgen receptor antagonist, for advanced metastatic prostate cancer.1

Financially, Eikon held $461.7 million in cash, cash equivalents, and marketable securities as of September 30, 2026,1 and said it expects this to fund operations into the first quarter of 2028.1 Net loss attributable to common stockholders was $86.1 million for the quarter, compared to $71.1 million a year earlier.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.